Pharmaceutical Distributor Liability in Russia and the EAEU. Criminal and Administrative Exposure for Imported Goods
The temperature data logger in a refrigerated truck malfunctions. The driver turns off the cooling unit for five hours — in transit, at night. A batch of biological preparations worth 3 million ₽ arrives with a compromised cold chain. The distributor stays silent and sells the batch. Three months later: a Roszdravnadzor inspection, a launched criminal case, and frozen corporate bank accounts. This is a recurring pattern in recent years.
With the introduction of the EAEU Good Distribution Practice (GDP) rules, the distributor’s zone of liability has expanded radically. Simply checking documents upon receipt is no longer enough. Regulators now require a fully managed quality system, a designated Responsible Person, and comprehensive documentation for every link in the supply chain. When this system is absent, an administrative fine can turn into a criminal case based on a single figure: the monetary value of the batch.
How Liability Worked Before GDP Standards
Before 2016, a Russian distributor’s liability was governed primarily by general commercial law. There were almost no specific statutory offenses for violations within the pharmaceutical supply chain. The main control mechanism was Ministry of Health Order No. 646n on good storage practices, but its requirements were confined strictly to the warehouse — transportation, outsourced logistics chains, and vendor management remained entirely outside the regulatory spotlight.
The Criminal Code already had Article 238 (production, storage, transportation, or sale of goods and services not meeting safety requirements), but its application to the pharmaceutical sector was rare: prosecutors had to prove that actual harm to a patient’s health had occurred. Consequently, most infractions resulted in nothing more than supervisory orders and trivial fines.
Everything shifted in 2015. Federal Law No. 532-FZ introduced Article 6.33 to the Code of Administrative Offenses (KoAP RF) and Article 238.1 to the Criminal Code (CC RF). Simultaneously, in 2016, the Council of the Eurasian Economic Commission (EEC) adopted Decision No. 80, approving the EAEU GDP Rules. The old Order No. 646n was officially phased out on May 20, 2025, replaced by Ministry of Health Order No. 260n dated April 29, 2025, operating in tandem with the EAEU GDP standards.
| Parameter | Before (Pre-2016) | Now |
|---|---|---|
| Distribution Standard | Order No. 646n — warehouse storage only | EAEU GDP — full end-to-end supply chain |
| Administrative Liability | General commercial regulations | Art. 6.33 KoAP RF — fines up to 5 million ₽ |
| Criminal Liability | Enforced only if actual health damage was proven | Art. 238.1 CC RF — triggered from a 100,000 ₽ threshold |
| Personal Liability | Not explicitly regulated | Designated Responsible Person of the distributor |
Three Administrative Offenses That Directly Threaten Distributors
The administrative system is straightforward: the closer a violation gets to the integrity of the physical product, the harsher the penalty.
Article 14.4.2 of the KoAP RF — violation of legislation governing the circulation of medicinal products. This is the «baseline» article for procedural failures in wholesale trade: failure to maintain temperature logs during storage, missing Standard Operating Procedures (SOPs), or violations of inbound receipt protocols. Under Part 1, fines for legal entities range from 20,000 ₽ to 30,000 ₽. Under Part 1.1 (introduced in 2023), fines jump to between 150,000 ₽ and 200,000 ₽, with company executives also facing potential disqualification for a term of 6 months to 1 year.
The figures look modest. In practice, Article 14.4.2 acts as an early indicator of systemic compliance failures: repeated citations under this article inevitably trigger scrutiny at Roszdravnadzor, leading to unannounced inspections specifically targeted at uncovering violations under the far more severe Article 6.33.
Article 6.33 of the KoAP RF — circulation of falsified, counterfeit, substandard, and unregistered medicinal products and medical devices. Fines for legal entities:
| Clause of Art. 6.33 | Offense | Fine for Legal Entities |
|---|---|---|
| Part 1 | Importation / sale of falsified or counterfeit medicinal products and medical devices | 1,000,000 – 5,000,000 ₽ or suspension of operations for up to 90 days |
| Part 2 | Importation / sale of substandard or unregistered medicinal products and medical devices | 1,000,000 – 5,000,000 ₽ or suspension of operations for up to 90 days |
| Part 3 | The same actions committed using mass media or the Internet | 2,000,000 – 6,000,000 ₽ or suspension of operations for up to 90 days |
Liability under Article 6.33 is triggered regardless of whether a patient suffered actual physical harm. The mere act of importing or selling products that do not conform to specifications constitutes the offense. For a distributor, this means any batch deviation caught during an inspection automatically generates a multi-million-ruble fine.
The statutory note to Article 6.33 provides a safe harbor: liability does not extend to unregistered medicinal products and medical devices if they are not manufactured in the Russian Federation, are recommended by the WHO, or if their import is explicitly permitted under special regulatory acts. Parallel imports under Government Decree No. 506 dated March 29, 2022, do not automatically qualify for this exemption — the specific products must be explicitly listed in the authorized registry.
Article 6.28 of the KoAP RF regulates violations of medical device circulation rules that do not fall under Article 6.33. Fines for legal entities range from 30,000 ₽ to 50,000 ₽. The relatively modest monetary penalty is compounded by the mandatory confiscation of the entire commercial batch of the unregistered medical devices.
When an Administrative Fine Turns into a Criminal Case
The boundary hinges on a single figure: 100,000 ₽. This is the exact statutory threshold for «large scale» established in the note to Article 238.1 of the Criminal Code (CC RF) — the value of medicinal products, medical devices, or dietary supplements exceeding this amount. Given the market value of standard commercial shipments, this threshold is crossed effortlessly: almost any import of substandard or unregistered products automatically enters criminal territory.
Article 238.1 of the CC RF — circulation of falsified, substandard, and unregistered medicinal products, medical devices, and distribution of falsified dietary supplements.
| Clause | Offense | Statutory Sanction |
|---|---|---|
| Part 1 | Production, sale, or importation for the purpose of sale on a large scale (exceeding 100,000 ₽) | Compulsory labor or imprisonment for 3 to 5 years, with a fine of 500,000 ₽ to 2,000,000 ₽ |
| Part 1.1 | The same actions committed using mass media or the Internet | Imprisonment for 4 to 6 years, with a fine of 750,000 ₽ to 2,500,000 ₽ |
| Part 2 | The same actions committed by an organized group, or resulting in serious health consequences or death | Imprisonment for 5 to 8 years, with a fine of 1,000,000 ₽ to 3,000,000 ₽ |
| Part 3 | Actions resulting in the death of two or more individuals | Imprisonment for 8 to 12 years, with a fine of 2,000,000 ₽ to 5,000,000 ₽ |
For a distributor, the fault element of the offense is intent (mens rea). Investigators will try to prove that the company knew, or legally should have known, about the product’s non-compliance and proceeded with distribution anyway. Operating without a functional GDP system creates a «presumption of awareness»: a professional market participant was obligated to detect the anomaly but failed to do so.
The conduct element (actus reus) does not require a completed sale. Courts routinely rule that having a signed supply contract with a pharmacy chain or a hospital while a compromised batch is still sitting in a warehouse constitutes preparation for sale — which by itself satisfies the criminal conduct requirement.
Article 238 of the CC RF is invoked when imported goods present a real threat to human life or health due to failure to meet safety requirements. A typical distributor scenario: cold chain failure during transit of biologics or vaccines. If a forensic analysis confirms that overheating caused a drug to become toxic, storing or transporting it for commercial purposes is prosecuted under Article 238. The maximum penalty where the actions result in the death of two or more individuals reaches 10 years of imprisonment.
Under Article 238, the 100,000 ₽ threshold is irrelevant: it is sufficient to prove that the product posed a real danger to human life.
GDP as a Risk Management System
EEC Council Decision No. 80 of November 3, 2016, established an architecture of structured corporate accountability. Three central elements directly dictate a distributor’s legal standing during an audit or criminal investigation.
The Designated Responsible Person (Paragraphs 17–21 of EAEU GDP). Senior management is legally required to appoint a Responsible Person with verified qualifications (ideally a formal pharmacy degree) and explicitly outline their authority in a job description. This individual may delegate daily tasks, but not their ultimate legal accountability. In practice, the Responsible Person is the primary target in administrative and criminal investigations. At the same time, a clearly defined role serves as an internal firewall, making it significantly harder for prosecutors to charge multiple company executives with acting as a group by prior conspiracy under Part 2 of Article 238.1.
The Documentation System (Paragraphs 52–61 of EAEU GDP). Written SOPs, batch testing records, temperature logs, and inbound/outbound records must be archived for at least 5 years and remain instantly accessible to inspectors. In judicial practice, missing temperature monitoring data anywhere along the route from a foreign manufacturing facility to a Russian warehouse is treated as a gross violation, stripping the distributor of any ability to argue good faith.
Supplier Qualification (Paragraphs 66–68 of EAEU GDP). Distributors are legally bound to source products exclusively from vendors holding valid manufacturing or distribution authorizations. Supplier evaluation processes must be thoroughly documented and periodically re-evaluated. Pleading ignorance of a supplier’s non-compliance will not hold in court if no supplier qualification audit was ever conducted.
What to Do
Audit your GDP infrastructure. Verify that a Responsible Person has been formally appointed with a current job description. Ensure that SOPs for inbound receipt, storage, and transport are actively used — not just filed away. If any of these elements is missing, Roszdravnadzor can issue a citation under Part 1.1 of Article 14.4.2 KoAP RF at the very first routine inspection.
Deploy continuous cold chain monitoring. For all thermolabile pharmaceuticals, mandate the use of temperature data loggers at every leg of transit — from the moment cargo leaves the foreign manufacturer until it is handed over to the end recipient. All data must be stored in a format available for export and submission to the regulator. Any gaps in the log are treated as storage temperature violations.
Execute a Quality Agreement with the manufacturer. Clearly define the foreign manufacturer’s obligation to immediately report any discovered batch defects in already-shipped series, stability test results, and toxicological assessments of components. This document is your primary instrument for a right-of-recourse claim and serves as critical evidence of corporate due diligence in court.
Qualify batches before market release. Implement a batch release protocol: the Responsible Person must formally sign off on full compliance with all requirements before any unit enters the commercial chain. Even if a batch sits in a warehouse without an active sales order, an incoming invoice paired with the absence of an official hold record can be interpreted by investigators as intent to sell.
Test your product recall system. EAEU GDP (Paragraph 105) requires the ability to initiate an emergency batch recall at any moment. Run a mock recall at least once a year. Lacking an operational recall mechanism is a standalone violation in its own right, and if a substandard batch is discovered while actively being sold, the absence of a recall process will be used by prosecutors as evidence of criminal intent.
The state is systematically tightening its grip on pharmaceutical and medical device supply chains. Administrative penalties under Article 6.33 KoAP RF can immediately reach 6 million ₽, while criminal exposure under Article 238.1 CC RF can result in up to 12 years of imprisonment. The criminal threshold of 100,000 ₽ no longer shields standard commercial shipments. Companies that treat GDP as a living risk-management system — rather than a stack of paperwork designed to pass an inspection — establish their good faith and due diligence long before investigators arrive with a search warrant.
Regulatory Framework:
1. Order of the Ministry of Health of the Russian Federation No. 260n dated April 29, 2025, «On Approval of the Rules for the Storage of Medicinal Products» (entered into force May 20, 2025)
2. Decision of the Council of the Eurasian Economic Commission No. 80 dated November 3, 2016, «On Approval of the Rules of Good Distribution Practice Within the Eurasian Economic Union» (as amended March 23, 2023)
3. Federal Law No. 61-FZ dated April 12, 2010, «On the Circulation of Medicinal Products» (as amended July 23, 2025)
4. Federal Law No. 323-FZ dated November 21, 2011, «On the Basics of Health Protection of Citizens in the Russian Federation» (as amended July 31, 2025)
5. Code of Administrative Offenses of the Russian Federation (KoAP RF): Articles 6.33, 6.28, 14.4.2 (as amended June 10, 2026)
6. Criminal Code of the Russian Federation (CC RF): Articles 238, 238.1 (as amended February 20, 2026)
7. Decree of the Government of the Russian Federation No. 506 dated March 29, 2022, «On Goods (Groups of Goods) in Respect of Which the Provisions of the Civil Code of the Russian Federation on the Protection of Exclusive Rights Cannot Be Applied»